Revenue (Tables)

3 Months Ended

Mar. 31, 2020

Disaggregation of Revenue [Abstract]

Disaggregation of Revenue [Table Text Block]

The following tables disaggregate our revenue from contracts with customers by business and geographic region (in millions):

	Three Months Ended March 31,
	2020						2019
Businesses	U.S.		OUS		Total		U.S.		OUS		Total
Endoscopy	$	256	$	186	$	442	$	253	$	187	$	440
Urology and Pelvic Health	237		95		332		231		94		326
Cardiac Rhythm Management	255		182		437		288		203		491
Electrophysiology	32		43		74		36		43		79
Neuromodulation	151		40		191		144		42		186
Interventional Cardiology	297		336		633		296		365		661
Peripheral Interventions	224		168		392		156		155		311
Specialty Pharmaceuticals	37		4		41		n/a		n/a		n/a
Net Sales	$	1,489	$	1,054	$	2,543	$	1,403	$	1,090	$	2,493

	Three Months Ended March 31,
Geographic Regions	2020		2019
U.S.	$	1,452	$	1,403
EMEA (Europe, Middle East and Africa)	552		561
APAC (Asia-Pacific)	409		437
LACA (Latin America and Canada)	89		92
Medical Devices	2,502		2,493
U.S.	37		n/a
OUS	4		n/a
Specialty Pharmaceuticals	41		n/a
Net Sales	$	2,543	$	2,493
Emerging Markets (1)	$	267	$	297

(1) We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Periodically, we assess our list of Emerging Markets, which is currently comprised of the following countries: Argentina, Brazil, Chile, China, Colombia, Czech Republic, India, Indonesia, Malaysia, Mexico, Philippines, Poland, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Thailand, Turkey and Vietnam.